OBJECTIVE: To assess the feasibility of utilizing dynamic contrast enhanced (DCE)-MRI for depicting the effects of N (G)-nitro-L -arginine methylester (L -NAME), a nitric oxide synthase (NOS) inhibitor, on glomerular filtration rate (GFR) in rats. Since Gd-DTPA is mainly cleared through the kidneys, a first-order kinetic model was used to estimate GFR based on a clearance index (k ( cl )) that describes the tracer transport rate from the renal cortex to the outer medulla. MATERIALS AND METHODS: Normotensive Sprague-Dawley rats were infused with either vehicle (0.9% NaCl) or one of three doses of L -NAME (1, 3 or 10 mg/kg) for 30 min prior to imaging. In a separate set of animals, systolic blood pressure (SBP) was measured for all treatment groups. RESULTS: L -NAME caused a significant increase in SBP at all doses when compared to pre-dose values and at the two highest doses, post-infusion, when compared to vehicle. Administration of L -NAME also led to dose-dependent changes in the rate of Gd-DTPA uptake and tracer concentrations reached in selected regions of the kidney. The k ( cl ) measurements indicated a significant impairment of GFR following NOS blockade at the highest dose of L -NAME. CONCLUSION: DCE-MRI method detected changes in GFR in response to NO inhibition with L -NAME. This non-invasive technique could be used in longitudinal studies in preclinical and clinical settings offering a rapid assessment of single-kidney function.
OBJECTIVE: To assess the feasibility of utilizing dynamic contrast enhanced (DCE)-MRI for depicting the effects of N (G)-nitro-L -arginine methylester (L -NAME), a nitric oxide synthase (NOS) inhibitor, on glomerular filtration rate (GFR) in rats. Since Gd-DTPA is mainly cleared through the kidneys, a first-order kinetic model was used to estimate GFR based on a clearance index (k ( cl )) that describes the tracer transport rate from the renal cortex to the outer medulla. MATERIALS AND METHODS: Normotensive Sprague-Dawley rats were infused with either vehicle (0.9% NaCl) or one of three doses of L -NAME (1, 3 or 10 mg/kg) for 30 min prior to imaging. In a separate set of animals, systolic blood pressure (SBP) was measured for all treatment groups. RESULTS:L -NAME caused a significant increase in SBP at all doses when compared to pre-dose values and at the two highest doses, post-infusion, when compared to vehicle. Administration of L -NAME also led to dose-dependent changes in the rate of Gd-DTPA uptake and tracer concentrations reached in selected regions of the kidney. The k ( cl ) measurements indicated a significant impairment of GFR following NOS blockade at the highest dose of L -NAME. CONCLUSION:DCE-MRI method detected changes in GFR in response to NO inhibition with L -NAME. This non-invasive technique could be used in longitudinal studies in preclinical and clinical settings offering a rapid assessment of single-kidney function.
Authors: Vivian S Lee; Henry Rusinek; Louisa Bokacheva; Ambrose J Huang; Niels Oesingmann; Qun Chen; Manmeen Kaur; Keyma Prince; Ting Song; Elissa L Kramer; Edward F Leonard Journal: Am J Physiol Renal Physiol Date: 2007-01-09
Authors: C L Dumoulin; M H Buonocore; L R Opsahl; R W Katzberg; R D Darrow; T W Morris; C Batey Journal: Magn Reson Med Date: 1994-09 Impact factor: 4.668
Authors: Michael Pedersen; Pietro Irrera; Walter Dastrù; Frank G Zöllner; Kevin M Bennett; Scott C Beeman; G Larry Bretthorst; Joel R Garbow; Dario Livio Longo Journal: Methods Mol Biol Date: 2021